NCT01255215View on ClinicalTrials.gov

Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2014

Conditions
Severe Malaria
Interventions
DRUG

Inhaled Nitric Oxide

Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)

Trial Locations (1)

Unknown

Jinja Regional Referral Hospital, Jinja

All Listed Sponsors
collaborator

Makerere University

OTHER

collaborator

University of Toronto

OTHER

lead

University Health Network, Toronto

OTHER

NCT01255215 - Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial | Biotech Hunter | Biotech Hunter